公开(公告)号：US20140127229A1

公开(公告)日：2014-05-08

申请号：US14055238

申请日：2013-10-16

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Allison Y. Luo ,  Wendy L. Trigona ,  Jinshan Shen ,  Li-An Xu ,  Yan Zhang ,  Bruce Stouffer ,  Haibin Chen ,  Haichun Huang ,  Xiaolu Tao ,  Catherine Brockus

IPC: G01N33/68

CPC classification number: G01N33/686 ,  A61K39/3955 ,  A61K2039/505 ,  C07K16/24 ,  C07K16/4208 ,  C07K2317/21 ,  C07K2317/76 ,  C07K2317/90

Abstract: In certain embodiments, the present invention provides a method of treating an IP-10-related disease in a subject, comprising: (a) administering to the subject a predetermined dosage of an anti-IP-10 antibody; (b) detecting the level of the anti-IP-10 antibody in a sample of the subject; and (c) if the level of the anti-IP-10 antibody from step (b) is below a threshold exposure level, increasing the dosage of the anti-IP-10 antibody in the subject such that the IP-10 related disease in the subject is treated. In certain embodiments, the present invention provides an isolated monoclonal anti-idiotypic antibody, or an antigen binding portion thereof, which binds to the anti-IP-10 antibody MDX-1100.

Abstract translation: 在某些实施方案中，本发明提供了治疗受试者中IP-10相关疾病的方法，包括：（a）向受试者施用预定剂量的抗-IP-10抗体; （b）检测受试者样品中抗-IP-10抗体的水平; 和（c）如果来自步骤（b）的抗-IP-10抗体的水平低于临界暴露水平，则增加受试者中抗-IP-10抗体的剂量使得IP-10相关疾病在 该主题得到对待。 在某些实施方案中，本发明提供了与抗-IP-10抗体MDX-1100结合的分离的单克隆抗独特型抗体或其抗原结合部分。

公开(公告)号：US09429581B2

公开(公告)日：2016-08-30

申请号：US14055238

申请日：2013-10-16

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Allison Y. Luo ,  Wendy L. Trigona ,  Jinshan Shen ,  Li-An Xu ,  Yan Zhang ,  Bruce Stouffer ,  Haibin Chen ,  Haichun Huang ,  Xiaolu Tao ,  Catherine Brockus

IPC: G01N33/68 ,  C07K16/24 ,  C07K16/42 ,  A61K39/395 ,  A61K39/00

CPC classification number: G01N33/686 ,  A61K39/3955 ,  A61K2039/505 ,  C07K16/24 ,  C07K16/4208 ,  C07K2317/21 ,  C07K2317/76 ,  C07K2317/90

Abstract: In certain embodiments, the present invention provides a method of treating an Interferon gamma inducible protein 10 (IP-10)-related disease in a subject, comprising: (a) administering to the subject a predetermined dosage of an anti-IP-10 antibody; (b) detecting the level of the anti-IP-10 antibody in a sample of the subject; and (c) if the level of the anti-IP-10 antibody from step (b) is below a threshold exposure level, increasing the dosage of the anti-IP-10 antibody in the subject such that the IP-10 related disease in the subject is treated. In certain embodiments, the present invention provides an isolated monoclonal anti-idiotypic antibody, or an antigen binding portion thereof, which binds to the anti-IP-10 antibody MDX-1100.

Abstract translation: 在某些实施方案中，本发明提供了治疗受试者中的干扰素γ诱导蛋白10（IP-10）相关疾病的方法，其包括：（a）向受试者施用预定剂量的抗-IP-10抗体 ; （b）检测受试者样品中抗-IP-10抗体的水平; 和（c）如果来自步骤（b）的抗-IP-10抗体的水平低于临界暴露水平，则增加受试者中抗-IP-10抗体的剂量使得IP-10相关疾病在 该主题得到对待。 在某些实施方案中，本发明提供了与抗-IP-10抗体MDX-1100结合的分离的单克隆抗独特型抗体或其抗原结合部分。